Bicara Therapeutics Inc. Common Stock
BCAX · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Assets | – | – | – | – |
| Cash & Equivalents | $172 | $437 | $462 | $490 |
| Short-Term Investments | $118 | $0 | $0 | $0 |
| Receivables | $0 | $0 | $0 | $0 |
| Inventory | $0 | $0 | $0 | $0 |
| Other Curr. Assets | $7 | $8 | $9 | $13 |
| Total Curr. Assets | $297 | $444 | $471 | $503 |
| Property Plant & Equip (Net) | $2 | $2 | $1 | $1 |
| Goodwill | $0 | $0 | $0 | $0 |
| Intangibles | $0 | $0 | $0 | $0 |
| Long-Term Investments | $117 | $0 | $0 | $0 |
| Tax Assets | $0 | $0 | $0 | $59 |
| Other NC Assets | $8 | $7 | $7 | $7 |
| Total NC Assets | $127 | $9 | $7 | $67 |
| Other Assets | $0 | $0 | $0 | $0 |
| Total Assets | $425 | $454 | $478 | $569 |
| Liabilities | – | – | – | – |
| Payables | $3 | $3 | $3 | $5 |
| Short-Term Debt | $1 | $1 | $1 | $1 |
| Tax Payable | $0 | $0 | $0 | $0 |
| Deferred Revenue | $0 | $0 | $0 | $0 |
| Other Curr. Liab. | $17 | $13 | $16 | $13 |
| Total Curr. Liab. | $21 | $17 | $19 | $18 |
| LT Debt | $1 | $1 | $0 | $0 |
| Deferred Rev, NC | $0 | $0 | $0 | $0 |
| Deferred Tax Liab, NC | $0 | $0 | $0 | $59 |
| Other NC Liab. | $0 | $0 | $0 | $0 |
| Total NC Liab. | $1 | $1 | $0 | $59 |
| Other Liabilities | $0 | $0 | $0 | $0 |
| Cap. Leases | $0 | $2 | $1 | $0 |
| Total Liabilities | $22 | $18 | $19 | $77 |
| Equity | – | – | – | – |
| Pref Stock | $0 | $0 | $0 | $0 |
| Common Stock | $0 | $0 | $0 | $0 |
| Retained Earnings | -$322 | -$285 | -$258 | -$221 |
| AOCI | -$0 | $0 | $0 | $0 |
| Other Equity | $724 | $720 | $717 | $713 |
| Total Equity | $403 | $435 | $459 | $492 |
| Supplemental Information | – | – | – | – |
| Minority Interest | $0 | $0 | $0 | $0 |
| Total Liab. & Tot. Equity | $425 | $454 | $478 | $569 |
| Net Debt | -$170 | -$434 | -$461 | -$489 |